Over 5 Years [Member] Operating Segments [Member] Operating segments [member] Current [Member] Classes of intangible assets other than goodwill [domain] Business combinations [Member] Business combinations [Member] Buildings [Member] Temporary differences [member] 1-5 Years [Member] Over Time [Member] Subsidiaries [domain] Types of share-based payment arrangements [domain] Accumulated Depreciation [Member] Accumulated depreciation and amortisation [member] Associates [domain] Other Countries [Member] Foreign countries [member] Share Capital [Member] Issued capital [member] Unrealized Foreign Exchange Gains [Member] At a Point in Time [Member] Unobservable inputs [domain] Liabilities arising from financing activities [domain] Right-of-Use Asset [Member] Right-of-use assets [member] Share Capital Reserve [Member] Capital reserve [member] Types of contracts [domain] Segments [domain] 1-6 Months [Member] Contingent Consideration [Member] Borrowings by name [domain] Discounted Cashflows [Member] 60 days [Member] Bottom of Range [Member] Minimum [Member] Bottom of range [member] Plant and Equipment [Member] Plant and Equipment [Member] Categories of financial liabilities [domain] 90 days [Member] Level 3 of Fair Value Hierarchy [Member] Level 3 of fair value hierarchy [member] Segment consolidation items [domain] Other Reserves [Member] Patents [Member] Temporary difference, unused tax losses and unused tax credits [domain] 30 days [Member] Brand Names [Member] Intellectuals Property [Member] Lease Liabilities [Member] Licences [Member] Other [Member] Other temporary differences [member] Maturity [domain] Components of equity [domain] Level 1 of Fair Value Hierarchy [Member] Level 1 [Member] Customer-related Intangible Assets [Member] Customer-related intangible assets [member] Tax Losses [Member] Business combinations [domain] Goodwill [Member] Furniture, Fittings and Equipment [Member] Default financial statements date [member] Range [domain] Motor Vehicles [member] Motor Vehicles [Member] Types of antidilutive instruments [domain] Reconciling Items [Member] Unallocated amounts [member] Due > 1 year [Member] Past due status [domain] Due 1 year [Member] Not later than one year [member] Foreign Currency Risk [Member] Valuation techniques used in fair value measurement [domain] Credit Risk [Member] Credit Risk [Member] Share-based payment reserve [Member] Classes of share capital [domain] Levels of fair value hierarchy [domain] Classes of assets [domain] Software [Member] Classes of financial instruments [domain] Accumulated depreciation, amortisation and impairment [member] Top of Range [Member] Maximum [Member] Top of range [member] Products and services [domain] Products and services [domain] Foreign currency translation reserve [Member] Types of risks [domain] Share Price [Member] Timing of transfer of goods or services [domain] Carrying amount [Member] Ordinary Shares [Member] Separate management entities [domain] Cost [Member] Leasehold Improvements [Member] Properties [Member] Land and Buildings [Member] Share Options [Member] Options [Member] Geographical areas [domain] 6-12 Months [Member] Classes of property, plant and equipment [domain] Income approach [member] Non-adjusting events after reporting period [domain] Accumulated Losses [Member] 120 days [Member] Granted during the year (in dollars per share) Weighted average exercise price of share options granted in share-based payment arrangement Acquisition of businesses Acquisitions through business combinations, other provisions Disclosure of information for cash-generating units [Abstract] Right-of-use assets [Abstract] Fair value measurement Total comprehensive income/(loss) for the year Comprehensive income Increase/(decrease) in profit before tax, financial liabilities (Increase) in inventory Adjustments for decrease (increase) in inventories Exchange differences Increase (decrease) through net exchange differences, right-of-use assets Payroll liabilities Total consideration Consideration transferred, acquisition-date fair value Liabilities Related to Contracts with Customers Disclosure of information for cash-generating units [line items] Revenue Revenue of acquiree since acquisition date Work in progress Additions Additions to right-of-use assets Borrowings Disclosure of borrowings [text block] Cash and cash equivalents Cash and cash equivalents Cash and cash equivalents at the beginning of the financial year Cash and cash equivalents at the end of the financial year Disclosure of associates [line items] Disclosure of quantitative information about right-of-use assets [line items] Finance costs Finance costs Finance costs Finance costs Acquisitions of businesses Non-current Lease liabilities Non-current lease liabilities Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Impairment of assets Trade and other payables Trade and other payables Total trade and other payables Trade and other payables Disclosure of trade and other payables [text block] Cash flows from financing activities Changes in equity [Abstract] Changes in equity [abstract] Ageing of Trade Receivables Total financial liabilities Disclosure of detailed information about business combination [line items] Unused tax losses and carried forward tax credits for which no deferred tax asset has been recognized [Abstract] Depreciation and amortization [Abstract] Revenue Description of accounting policy for recognition of revenue [text block] Exercised during the year (in dollars per share) Exercise price (in dollars per share) Other income Other income Total commitments Capital commitments Intangible assets [Abstract] Intangible assets other than goodwill [abstract] Closing balance Provisions Non-current Non-current provisions Inventories Disclosure of inventories [text block] Inventories Total inventories Current inventories Other current assets Disclosure of other current assets [text block] Property, plant and equipment Ending balance Beginning balance Weighted average ordinary shares (in shares) Weighted average number of ordinary shares used as the denominator in calculating basic earnings/loss per share (in shares) Weighted average number of ordinary shares used in calculating basic earnings per share Intangible assets Description of accounting policy for intangible assets and goodwill [text block] Finance income Non-current assets Non-current assets [abstract] Exchange differences Increase (decrease) through net exchange differences, intangible assets other than goodwill Other receivables Other current receivables Current tax payable Operating Segment Description of cash-generating unit Recognized amounts of identifiable assets acquired and liabilities assumed [Abstract] Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] Provisions Description of accounting policy for provisions [text block] Difference in overseas tax rates Tax effect of foreign tax rates Disclosure of nature and extent of risks arising from financial instruments [line items] Revenue from contracts with customers [Abstract] Owners of Telix Pharmaceuticals Limited Disclosure of transactions between related parties [line items] Prior year tax losses recognized Adjustments for deferred tax of prior periods Total basic earnings/(loss) per share attributable to the ordinary equity holders of the Company (in dollars per share) Basic earnings (loss) per share Current year tax losses not recognized Tax effect of tax losses Interest received Total non-current assets Non-current assets Right-of-use assets Disclosure of quantitative information about right-of-use assets [text block] Property, Plant and Equipment Disclosure of detailed information about property, plant and equipment [text block] Options exercised (in shares) Exercised during the year (in shares) Number of share options exercised in share-based payment arrangement Trade and other payables Description of accounting policy for trade and other payables [text block] Trade and other receivables Disclosure of trade and other receivables [text block] Disclosure of detailed information about intangible assets [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Disclosure of disaggregation of revenue from contracts with customers [line items] Items that will not be reclassified to profit or loss in subsequent periods: Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Operating profit/(loss) Profit (loss) from operating activities Contingent consideration Description of accounting policy for contingent liabilities and contingent assets [text block] Transaction costs of borrowings or capital raising Transaction costs Payments for debt issue costs Right-of-use assets [Abstract] Reconciliation of changes in right-of-use assets [abstract] (Decrease) in contract liabilities Research and development costs Impairment recognized Impairment loss recognised in profit or loss, goodwill Principal element of lease payments Cash outflow for leases Payments of lease liabilities, classified as financing activities Provisions Disclosure of provisions [text block] Movements in Deferred Tax Assets and Liabilities Cash flows from investing activities Percentage of increase/(decrease) in the share price of each financial liability Restricted cash Non-current restricted cash and cash equivalents Depreciation and Amortization Disclosure of depreciation and amortisation expense [text block] Options issued under EIP Useful lives of intangible assets Useful lives of acquired intangible assets Disclosure of detailed information about borrowings [line items] Consolidated statement of changes in equity [Abstract] Acquisition of businesses Acquisitions through business combinations, property, plant and equipment Fair value Total comprehensive income/(loss) for the year attributable to: Equity Disclosure of share capital, reserves and other equity interest [text block] General and administration costs General and administrative expense Net cash inflow/(outflow) Business combinations [Abstract] Acquisitions [Abstract] Number of fully paid shares issued (in shares) Capital commitments [abstract] Net proceeds Equity issued Equity issued Payments for acquisition of subsidiaries, net of cash acquired Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities Payments for investments in financial assets Purchase of financial instruments, classified as investing activities Provisions Total provisions Ending balance Beginning balance Profit/(loss) Receipts from customers Depreciation charge Depreciation, property, plant and equipment Capital commitments Contractual capital commitments Payment for provision of services in relation to business development Amount incurred by entity for provision of key management personnel services provided by separate management entity Equity Reserve of exchange differences on translation (Charged)/credited to profit and loss Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [abstract] Maturity date Bonds maturity Reconciliation of Liabilities Arising from Financing Activities Royalty income Increase in employee benefit obligations Total trade and other receivables Trade and other receivables Intangible assets Disclosure of intangible assets [text block] Profit/(loss) for the year attributable to: Assets Assets [abstract] Prima-facie tax rate Average effective tax rate Financial assets Non-current financial assets Number and Weighted Average Exercise Price of Stock Options Issue of shares Shares issued Income taxes paid Income taxes paid (refund), classified as operating activities Income tax (benefit)/expense Income tax (expense)/benefit Tax expense (income) Other comprehensive income: Numerical reconciliation of prima facie tax payable to income tax expense/(benefit) [Abstract] Gross profit Gross profit Trade and other receivables Trade and other current receivables General and administration costs Inventories Inventory recognised as of acquisition date Principal Subsidiaries Intangible assets [Abstract] Currency Risk Exposure Issue of convertible bonds Issue of convertible instruments Net cash used in investing activities Cash flows from (used in) investing activities Ownership interest held by the Group Other losses (net) Other gains/(losses) (net) Total other losses/(gains) (net) Unrecognized income tax benefit Unused tax losses for which no deferred tax asset recognised Cash and cash equivalents Cash and cash equivalents recognised as of acquisition date Research and development costs Research and development expense Schedule of Classes of Share Capital Disclosure of classes of share capital [text block] Employment costs [Abstract] Secured bank loans current Decommissioning liability Provision for decommissioning, restoration and rehabilitation costs Earnings per share [line items] Remuneration of auditor [Abstract] Contractual Maturity of Financial Instrument Liabilities Fair value of assets acquired and liabilities assumed at the acquisition date Disclosure of detailed information about business combination [text block] Total liabilities Total liabilities Provisions [Abstract] Current tax asset Total employment costs Employee benefits expense Disclosure of maturity analysis for non-derivative financial liabilities [abstract] Consolidated statement of financial position [Abstract] Transactions with Other Related Parties Total identifiable assets and liabilities Identifiable assets acquired (liabilities assumed) Intellectual property Identifiable intangible assets recognised as of acquisition date Total assets Total assets Events occurring after the reporting period [Abstract] Borrowings [Abstract] Trade and other payables [Abstract] Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items] Provision utilized Provision used, other provisions Revenue from Sale and Transfer of Goods and Services Disclosure of disaggregation of revenue from contracts with customers [text block] Adjusting items [Abstract] Adjustments for [Abstract] GST receivables Current receivables from taxes other than income tax Interest expense Interest expense Net cash from/(used in) operating activities Cash flows from (used in) operating activities Financial risk management Deduct trade and other payables capitalized to intangible assets Events occurring after the reporting period Disclosure of other provisions [line items] Deferred tax assets Net deferred tax assets Additions to non- current assets Disclosure of maturity analysis for non-derivative financial liabilities [line items] Exchange differences Increase (decrease) through net exchange differences, property, plant and equipment Sundry items Other tax effects for reconciliation between accounting profit and tax expense (income) Dividend yield Reconciliation of changes in other provisions [abstract] Remuneration of auditor Proceeds from issue of shares and other equity Changes in the fair value of investments at fair value through other comprehensive income Financial assets at fair value through loss Number of Options Issued under Equity Incentive Plan Outstanding Disclosure of terms and conditions of share-based payment arrangement [text block] Useful lives of assets Ending balance Total contract liabilities Beginning balance Contract liabilities Opening balance Closing balance Total convertible bond liability Liabilities arising from financing activities Raw materials and stores Disclosure of research and development costs [abstract] Contract liabilities Current Current contract liabilities Reconciliation of changes in intangible assets other than goodwill [Abstract] Disclosure of terms and conditions of share-based payment arrangement [line items] Share-based payments Purchases of intangible assets Purchase of intangible assets, classified as investing activities Material accounting policy information Depreciation and amortization Adjustments for depreciation and amortisation expense Repayment of borrowings Repayments of borrowings, classified as financing activities Related party transactions EIP options issued (in shares) Granted during the year (in shares) Issued during the year (in shares) Right-of-use assets Balance at the end Balance at the beginning Right-of-use assets Financial assets [Abstract] Disclosure of financial assets [abstract] Diluted earnings per share [Abstract] Contingent consideration Contingent value rights Liabilities incurred Earnings per share Description of accounting policy for earnings per share [text block] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [line items] Statement of changes in equity [line items] Property, plant and equipment [Abstract] (Increase) in trade and other receivables Transaction cost Payments for share issue costs Depreciation Intangible Assets Disclosure of detailed information about intangible assets [text block] Net loss Net loss Transactions with other related parties [Abstract] Acquisition of business Acquisitions through business combinations, intangible assets other than goodwill Revenue recognized Revenue that was included in contract liability balance at beginning of period Business combinations Share capital [Abstract] Total Current assets Current assets [abstract] Trade and other receivables [Abstract] Employee benefit obligations [Abstract] Cash flows from operating activities Reconciliation of profit (loss) after income tax to net cash from (used in) operating activities [Abstract] Payments to suppliers and employees Payments to suppliers for goods and services and to and on behalf of employees Revenues and Adjusted EBITDA and Group Adjusted EBITA, by Segments Consolidated statement of cash flows [Abstract] Beginning balance Ending balance Intangible assets other than goodwill Intangible assets other than goodwill Impairment reversals Income tax expense/(benefit) [Abstract] Other non-current assets Other non-current assets Total equity Beginning balance Ending balance Equity Consolidated statement of comprehensive income or loss [Abstract] Borrowings Disclosure of detailed information about borrowings [text block] Balance at beginning (in dollars per share) Balance at ending (in dollars per share) Weighted average exercise price of share options outstanding in share-based payment arrangement Share Based Compensation Expense Explanation of effect of share-based payments on entity's profit or loss [text block] Intangible assets Adjustment for current tax of prior periods Disclosure of non-adjusting events after reporting period [line items] Purchases of property, plant and equipment Purchase of property, plant and equipment, classified as investing activities Employee benefits Total lease liabilities Lease liabilities Ending balance Beginning balance Lease liabilities Share price at grant date (in dollars per share) Segment reporting Disclosure of detailed information about property, plant and equipment [line items] Total current assets Current assets Profit/(loss) before income tax Profit/(loss) before income tax Acquisitions Current tax expense Current Lease liabilities Current lease liabilities Secured bank loans non-current Other creditors Earnings per share Inventory expense Additions Additions other than through business combinations, property, plant and equipment Reconciliation of liabilities arising from financing activities [Abstract] Disclosure of reconciliation of liabilities arising from financing activities [abstract] Undrawn borrowing facilities Accumulated losses Risk adjusted post tax discount rate Discount rate used in current estimate of value in use Options lapsed (in shares) Number of share options forfeited in share-based payment arrangement Geographical Information Key Management Personnel Compensation Disclosure of information about key management personnel [text block] Other (gains)/losses (net) Disclosure of other operating income (expense) [text block] Place of business/country of incorporation Disclosure of classes of share capital [line items] Total current liabilities Current liabilities Establishment fee costs Amortization charge Amortisation, intangible assets other than goodwill Percentage of increase/(decrease) in financial asset Earnings per share [Abstract] Deferred tax liabilities Net deferred tax liabilities Government rebates payable Increase/(decrease) in other comprehensive income, financial assets Deferred tax benefit Deferred tax Net foreign exchange differences Share-based payments to employees Increase (decrease) through share-based payment transactions, equity Total revenue from continuing operations Revenue Beginning balance (in shares) Ending balance (in shares) Number of fully paid ordinary issued (in shares) Profit/(Loss) for the year Profit/(loss) for the year Property, plant and equipment Description of accounting policy for property, plant and equipment [text block] Useful life Description of useful life, intangible assets other than goodwill Property, plant and equipment Property, plant and equipment recognised as of acquisition date Superannuation Post-employment benefit expense in profit or loss Exercise price (in dollars per share) Exercise price, share options granted Trade and other payables Trade and other payables recognised as of acquisition date Trade receivables Current trade receivables Unrecognized deferred tax assets [Abstract] Share based payments Sales Taxes and Goods and Services Tax (GST) Income tax Basic earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share) Basic earnings/(loss) per share from continuing operations attributable to the ordinary equity holders of the Company (in dollars per share) Revenue from contracts with customers Revenue by location of customer Revenue from contracts with customers Borrowings Non-current Total borrowings non-current Prima-facie tax at a rate Financial assets Disclosure of financial instruments [text block] Employee benefit obligations Disclosure of employee benefits [text block] Deferred tax assets and liabilities [Abstract] Impairments Impairment loss recognised in profit or loss, intangible assets other than goodwill Total Income tax relating to components of other comprehensive income Other comprehensive income (loss) Other comprehensive income Revaluation - gross Related party transactions [Abstract] Amortization of intangible assets Income tax expense/(benefit) Salaries and wages Wages and salaries Basic earnings per share [Abstract] Basic earnings per share [abstract] Segment reporting [Abstract] (Increase)/decrease in other current assets Term Option life, share options granted Gross carrying amount Trade receivables Trade receivables Remuneration of auditor Auditor's remuneration Operating Segment Assets and Liabilities Disclosure of products and services [line items] Earnings Per Share Earnings per share [text block] Acquisition costs Acquisition costs Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination Non-current liabilities Non-current liabilities [abstract] Purchases of other non-current assets Purchase of other long-term assets, classified as investing activities Exchange differences on translation of foreign operations Other current assets [Abstract] Borrowings Due less then 1 year Current Total borrowings current Commitments Government grant liability Government grants Acquisition of contingent consideration for future earn-out payments Total non-current liabilities Non-current liabilities Consideration [Abstract] Consideration [Abstract] Acquisition-date fair value of total consideration transferred [abstract] Bonds issued Other non-current assets Non-current assets recognised as of acquisition date Convertible bond interest expense Interest expense Interest expense on bonds Government grants Description of accounting policy for government grants [text block] Audit or review of financial statements Property, plant and equipment Disclosure of property, plant and equipment [text block] Contingent liabilities Deferred Tax Assets and Liabilities Treasury share acquired Purchase of treasury shares Contract liabilities Non-current Non-current contract liabilities Anti-dilutive shares (in shares) Number of potential ordinary shares that are antidilutive in period presented Balance at ending (in shares) Balance at beginning (in shares) Number of share options outstanding in share-based payment arrangement Risk-free rate Risk free interest rate, share options granted Foreign exchange losses Percentage of ownership Proportion of ownership interest in associate Lease liabilities [Abstract] Selling and marketing expenses Sales and marketing expense Depreciation and amortization Depreciation and amortization Trade payables Trade payables Other current assets Total other current assets Disclosure of operating segments [line items] Cash flow information Key judgements and estimates Summary of Revenues from External Customers by Product and Geographic Region [Abstract] Disaggregation of Revenue from Contracts with Customers [Abstract] Employee Benefit Obligations Disclosure of defined benefit plans [text block] Borrowings Carrying amount Borrowings Borrowings Financial assets [Abstract] Cash paid Cash paid Cash payable Other non-cash movements Owners of Telix Pharmaceuticals Limited Comprehensive income, attributable to owners of parent Current liabilities Current liabilities [abstract] Net cash provided by financing activities Cash flows from (used in) financing activities Total diluted earnings/(loss) per share attributable to the ordinary equity holders of the Company (in dollars per share) Diluted earnings (loss) per share Unwind of discount Increase (decrease) through change in discount rate, other provisions Property, plant and equipment [Abstract] Reconciliation of changes in property, plant and equipment [abstract] Acquisition transaction costs Diluted earnings/(loss) per share from continuing operations after income tax attributable to the ordinary equity holders of the Company (in dollars per share) Diluted earnings/(loss) per share from continuing operations attributable to the ordinary equity holders of the Company (in dollars per share) Depreciation charge Depreciation charge on right-of-use assets Depreciation, right-of-use assets Financial assets Disclosure of financial assets [text block] Non-derivative financial liabilities Trade and other receivables Description of accounting policy for trade and other receivables [text block] Other assurance services Interest paid Interest paid, classified as operating activities Financial risk management [Abstract] Convertible bonds Unsecured convertible bonds non-current Grant date Provisions Current Current provisions Share based payments [Abstract] Contingent liabilities [Abstract] Expense from Share-based Payment Transactions [Abstract] Liabilities Liabilities [abstract] Unsecured convertible bonds current Proceeds from borrowings Convertible bonds interest rate Property plant and equipment [Abstract] Restricted cash Goodwill Goodwill recognised as of acquisition date Recognized Fair Values Exchange differences Increase (decrease) through net exchange differences, other provisions Lease liabilities Disclosure of leases [text block] Percentage of voting rights Volatility Contract liabilities [Abstract] Lapsed during the year (in shares) Number of share options expired in share-based payment arrangement Bank fees Cost of sales Cost of sales Superannuation entitlements Key management personnel compensation, post-employment benefits Key management personnel compensation Key management personnel compensation Additions Increase through new leases, liabilities arising from financing activities Total increase (decrease) in equity Increase (decrease) in equity Equity Equity [Abstract] Revenue from contracts with customers Disclosure of revenue from contracts with customers [text block] Share price (in dollars per share) Ordinary shares issued per share (in dollars per share) Accruals Other current assets Current assets recognised as of acquisition date Share-based payment charge Expense from share-based payment transactions with employees Other reserves Cash and cash equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Finished goods Weighted average number of shares used as the denominator [Abstract] Reclassifications Borrowings Description of accounting policy for borrowings [text block] Sensitivity Analysis Sensitivity analysis for types of market risk [text block] Prepayments Current prepayments Interest expense on lease liabilities Total lease interest Interest expense Trade creditors Net assets Assets (liabilities) General and administration costs [Abstract] Fair Value of Grant Date Inputs for Options Granted Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Items to be reclassified to profit or loss in subsequent periods: Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Inventories Description of accounting policy for measuring inventories [text block] Share-based payments Adjustments for share-based payments Professional fees Total unrecognized deferred tax assets Net increase in cash held Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Lease payments (principal and interest) Cash outflow for leases Share capital Beginning balance Ending balance Inventories [Abstract] Additions Additions other than through business combinations, intangible assets other than goodwill Financial assets Weighted average number of ordinary shares used as the denominator in calculating diluted earnings/loss per share (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Fair value remeasurement of provisions Disclosure of reconciliation of liabilities arising from financing activities [line items] Sale of goods Issue of shares on exercise of options Foreign currency translation Other advisory services Finance costs Disclosure of finance cost [text block] Short-term employee benefits Temporary difference, unused tax losses and unused tax credits [axis] Classes of property, plant and equipment [axis] Types of contracts [axis] Geographical areas [axis] Classes of assets [axis] Borrowings by name [axis] Borrowings by name [axis] Categories of financial liabilities [axis] Classes of financial instruments [axis] Valuation techniques used in fair value measurement [axis] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Classes of intangible assets other than goodwill [axis] Levels of fair value hierarchy [axis] Unobservable inputs [axis] Types of share-based payment arrangements [axis] Classes of share capital [axis] Associates [axis] Creation date [axis] Subsidiaries [axis] Segment consolidation items [axis] Liabilities arising from financing activities [axis] Products and services [axis] Products and services [axis] Timing of transfer of goods or services [axis] Maturity [axis] Business combinations [axis] Non-adjusting events after reporting period [axis] Separate management entities [axis] Range [axis] Components of equity [axis] Past due status [axis] Types of risks [axis] Types of antidilutive instruments [axis] Segments [axis] Earnings per share [table] Statement of changes in equity [table] Disclosure of classes of share capital [table] Disclosure of non-adjusting events after reporting period [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Disclosure of detailed information about property, plant and equipment [table] Disclosure of transactions between related parties [table] Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [table] Disclosure of associates [table] Disclosure of information for cash-generating units [table] Disclosure of other provisions [table] Disclosure of detailed information about intangible assets [table] Disclosure of reconciliation of liabilities arising from financing activities [table] Disclosure of sensitivity analysis of fair value measurement to changes in unobservable inputs, assets [table] Disclosure of disaggregation of revenue from contracts with customers [table] Disclosure of quantitative information about right-of-use assets [table] Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of detailed information about business combination [table] Disclosure of nature and extent of risks arising from financial instruments [table] Disclosure of maturity analysis for non-derivative financial liabilities [table] Disclosure of detailed information about borrowings [table] Disclosure of operating segments [table] Disclosure of products and services [table] Cover [Abstract] Document Type Document Annual Report Document Transition Report Document Shell Company Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current Document Registration Statement Document Accounting Standard Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Emerging Growth Company Entity Ex Transition Period Entity Addresses [Table] Entity Addresses, Address Type [Axis] Address Type [Domain] Business Contact [Member] Entity Addresses [Line Items] Contact Personnel Name Entity Address, Address Line One Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Firm ID Auditor Location AUD [Member] Australia, Dollars CAD [Member] Canada, Dollars CHF [Member] Switzerland, Francs EUR [Member] Euro Member Countries, Euro GBP [Member] United Kingdom, Pounds JPY [Member] Japan, Yen USD [Member] United States of America, Dollars All Currencies [Domain] Title and Position [Domain] Currency [Axis] Title and Position [Axis] Australia [Member] AUSTRALIA Belgium [Member] BELGIUM Canada [Member] CANADA China [Member] CHINA United Kingdom [Member] UNITED KINGDOM United States [Member] UNITED STATES Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Processes Integrated [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] The disclosure of detailed information about employment costs. Disclosure of detailed information about employment costs [Table Text Block] Employment Costs The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. Short-term incentives Short term incentives The amount of salaries and wages recognized in cost of sales. Salaries and wages included in cost of sales Salaries and wages included in cost of sales The amount of fees paid or payable to Non-executive directors. Non-executive directors fees Non-Executive Directors' fees The amount of expense arising from sales commissions. Sales commissions Sales commissions The entire disclosure for employment costs. Disclosure of employment costs explanatory [Text Block] Employment costs Tabular disclosure of information about provisions. Disclosure of information about provisions [Table Text Block] Provisions The amount of accrued royalties classified as current. Accrued royalties classified as current Accrued royalties The tabular disclosure of information about trade and other payables. Disclosure of trade and other payables explanatory [Table Text Block] Trade and Other Payables The disclosure of detailed information about general and administrative costs. Disclosure of detailed information about general and administration costs explanatory [Text Block] General and Administration Costs This member stands for a product or business unit. QSAM (153Sm-DOTMP) [Member] QSAM (153Sm-DOTMP) [Member] This member stands for a product or business unit. TLX591-C Dx (Illuccix) [Member] TLX591-CDx (Illuccix) [Member] This member stands for a product or business unit. TLX66 [Member] TLX66 [Member] This member stands for a product or business unit. SENSEI [Member] SENSEI [Member] This member stands for a product or business unit. IsoTherapeutics [Member] IsoTherapeutics [Member] This member stands for a cash-generating unit. TLX66-C Dx [Member] TLX66-C Dx [Member] This member stands for a product or business unit. TLX101 [Member] TLX101 [Member] This member stands for a product or business unit. TLX300 [Member] TLX300 [Member] This member stands for a product or business unit. Dedicaid QDOSE [Member] Dedicaid, QDOSE [Member] This member stands for a product or business unit. Brussels south and optimal tracers [Member] Brussels South and Optimal Tracers [Member] This member stands for announced a strategic investment in Mauna Kea to develop new hybrid pharmaceutical-device products through the combination of Telix's cancer-targeting agents with Mauna Kea's surgical endomicroscopy platform. Mauna Kea Technologies [Member] This member stands for the name of financial institution which company made loan agreement. HSBC bank australia limited [Member] HSBC Bank Australia Limited [Member] The amount of maximum borrowing facilities that may be available for operating activities and to settle capital commitments. Maximum borrowing facility Maximum borrowing facility Working capital facility [Abstract] Working capital facility [Abstract] The amount recognised as of the acquisition date for estimated identifiable assets acquired or liabilities assumed in a business combination. Estimated amounts of identifiable assets and acquired liabilities assumed Estimated amounts of identifiable assets and acquired liabilities assumed The amount recognised as of the business combination's acquisition date for goodwill and intangible assets. Goodwill and intangible assets recognised as of acquisition date Goodwill and intangible assets The period of measurement from the date of acquisition to the date the group obtains complete information about facts and circumstances that existed as of the acquisition date. Measurement period Measurement period This member stands for share based payments. Share based payments [Member] Share-based Payments [Member] This member stands for tax losses and tax credits. Tax losses and tax credits [Member] Tax Losses and Tax Credits [Member] This member stands for provisions. Provisions [Member] Provisions [Member] This member stands for intangible assets. Intangible assets [Member] Intangible Assets [Member] This member stands for inventory. Inventory [Member] Inventories [Member] This member stands for employee benefit obligations. Employee benefit obligations [Member] Employee Benefit Obligations [Member] The increase (decrease) in deferred tax liabilities pursuant to set-off provisions. Deferred tax assets pursuant to set-off provisions Set-off of deferred tax assets pursuant to set-off provisions The amount of tax expense or income relating to changes in deferred tax liabilities recognized on acquisition. Deferred tax liability on acquisition (Charged)/credited on acquisition Amount of deferred tax assets, before deferred tax asset attributable to taxable differences with provisions. Deferred tax asset gross Balance at the end Balance at the beginning Amount of deferred tax liabilities, before deferred tax liabilities attributable to taxable differences with provisions. Deferred tax liabilities gross Balance at the end Balance at the beginning The amount of tax expense or income relating to changes in deferred tax liabilities recognized in profit or loss. Deferred tax liability deferred tax expense income recognized in profit or loss (Charged)/credited to profit and loss The increase (decrease) in deferred tax assets pursuant to set-off provisions. Deferred tax liabilities pursuant to set-off provisions Set-off of deferred tax liabilities pursuant to set-off provisions Deferred tax assets [Abstract] Deferred tax liability [Abstract] Deferred tax liabilities [Abstract] The disclosure of unrecognized tax losses Unrecognized tax losses [Table Text Block] Unrecognized Tax Losses The disclosure of unrecognized deferred tax assets. Unrecognized deferred tax assets [Table Text Block] Unrecognized Deferred Tax Assets The exercise price of incentive securities in exchange for forfeited securities. Exercise price of incentive securities in exchange for forfeited securities Exercise price of incentive securities in exchange for forfeited securities (in dollars per share) Number of shares issued upon exercise of each convertible security under Equity Incentive Plan. Number of shares issued upon exercise of each convertible security Number of shares issued upon exercise of each convertible security (in shares) Equity incentive plan and options [Abstract] Equity Incentive Plan and Options [Abstract] The disclosure of detailed information about remuneration of auditor. Disclosure of detailed information about remuneration of auditor [Text Block] Remuneration of auditor The change in equity resulting from the issuing of convertible bonds. Increase (decrease) through Issue of convertible bonds Issue of convertible bonds (in shares) Amount of shares allocated to employees. Shares allocated to employees, value Shares allocated to employees Shares allocated to employees during the period. Increase (decrease) through shares allocated to employees Shares allocated to employees (in shares) The increase (decrease) in equity resulting from the transaction costs arising on Convertible Bonds Issue, shares. Increase (decrease) through transaction costs arising on convertible bonds issue, shares Transaction costs arising on convertible bonds issue (in shares) The increase (decrease) in equity resulting from treasury share transactions. Increase (decrease) through treasury shares acquired Treasury shares acquired (in shares) Share capital reserve [Abstract] Share capital [Abstract] Percentage of share options granted to performance-based stock awards holders out of the target. Share-based compensation arrangement by share-based payment award, options granted percentage Percentage of options granted to PSARs Fair value of share options granted during the period. Fair value of stock options granted Fair value (in dollars per share) The consideration of share options granted. Consideration share options granted Consideration Share based compensation arrangement, grant date fair value assumptions [Abstract] The disclosure of information about operating lease liabilities. Disclosure of operating lease payments [Table Text Block] Lease Payments The disclosure of information about lease liabilities. Disclosure of information about lease liabilities [Table Text Block] Lease Liabilities Contingent consideration valuation [Abstract] Contingent Consideration Valuation [Abstract] This member stands for milestone achievement probability of success factor used as a measurement input. Milestone achievement probability of success factor [Member] One five percent in post-tax discount rate contingent consideration. Percentage of post-tax discount rate contingent consideration Percentage of post-tax discount rate contingent consideration This member stands for expected sales volumes ARTMS and Telix products used as a measurement input. Expected sales volumes ARTMS and Telix products [Member] Expected Sales Volumes ARTMS and Telix Products [Member] The date termination on earn-out payments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Date of termination of earn-outs Future payment contingent on milestone [Abstract] Future Payment Contingent on Milestone [Abstract] The Group entered into a strategic commercial partnership with Grand Pharmaceutical Group Limited (Grand Pharma or GP, formerly known as China Grand Pharma or CGP) for the Group's portfolio of targeted radiation products. Grand pharmaceutical group limited [Member] Grand Pharmaceutical Group Limited [Member] The amount of the non-refundable upfront payment received. Non refundable upfront payment received Non-refundable upfront payment received Grand Pharma strategic partnership [Abstract] The entire disclosure for deferred tax assets and liabilities. Disclosure of deferred tax assets and liabilities [Text Block] Deferred tax assets and liabilities Contingent consideration amount of unwind discount during the year. Contingent consideration amount of unwind discount Unwind of discount Contingent consideration amount of exchange difference during the year. Contingent consideration amount of exchange differences Exchange differences The cash outflow for the payments of contingent consideration, classified as operating and investing activities. Payments for contingent consideration, classified as operating and investing activities Payments for contingent consideration The contingent consideration amounts adjusted to intangible assets during the year. Contingent consideration amounts adjusted to intangible assets Amounts adjusted to intangible assets The amount of contingent consideration charged to profit or loss during the year. Contingent consideration charged to profit or loss Charged to profit or loss The adjusted amount of contingent consideration during business acquisition. Business acquisition contingent consideration transferred Acquisition of businesses Detailed information about contingent consideration [Abstract] The amount of impairment loss (impairment reversals) of intangible assets. Impairment loss (impairment reversals) of intangible assets Impairments/(impairment reversals) of intangible assets The amount of realized currency exchange (losses) gains. Realized currency (loss)/gain Realized currency gain The remeasurement amount of contingent consideration during the year. Remeasurement of contingent consideration Remeasurement of contingent consideration The amount of unrealized foreign exchange losses (gains). Unrealized foreign exchange losses (gains) Unrealized currency (gain)/loss The period used for discounting the expected future cash flows for each program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Discounted expected future cash flows period Discounted expected future cash flows period The increase (decrease) in intangible assets other than goodwill resulting from reclassification. Reclassifications increase (decrease), intangible assets other than goodwill Reclassifications This member stands for a class of intangible assets representing customer relationships and brands. Customer relationships and brands [Member] Customer Relationships and Brands [Member] Amount of accumulated amortization for intangible assets used in the normal conduct of business. Accumulated amortization intangible assets Accumulated amortization The increase (decrease) in intangible assets other than goodwill resulting from changes in provision. Increase decrease through changes in provisions intangible assets other than goodwill Changes in provisions Amount before accumulated amortization of intangible assets used in the normal conduct of business and not intended for resale. Intangible assets at cost Cost The disclosure of detailed information about intangible assets to each cash generating unit. Disclosure of detailed information about intangible assets to each cash generating unit [Table Text Block] Allocation of Intangible Assets to Each Cash Generating Unit The disclosure of depreciation charge on right-of-use assets. Depreciation charge on right-of-use assets [Table Text Block] Depreciation Charge on Right-of-Use Assets The disclosure of quantitative information about right-of-use assets reconciliations of written down values. Disclosure of quantitative information about right of use assets reconciliations of written down values [Table Text Block] Right-of-Use Assets Name of the entity controlled by another entity. Next-Generation Therapeutic Assets [Member] Next-Generation Therapeutic Assets [Member] The number of products to be developed for royalties and sublicense fees payment. Number of products to be developed for royalties and sublicense fees payment Number of products to be developed for royalties and sublicense fees payment The amount recognized as of the acquisition date for deferred payment in equity as consideration in a business combination. Deferred payment in equity Deferred payment The indemnity period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Indemnity period Indemnity period This member stands for or Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued. Subsequent events [Member] Subsequent Event [Member] Title and position of individual or group within organization. Managing Director and Group Chief Executive Officer [Member] Dr. Christian Behrenbruch [Member] The percentage of ownership interest. Percentage of ownership interest Percentage of ownership interest This member stands for a classification of grant date share based payment. Grant Date Forty One [Member] Grant Date 25-Nov-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-eight [Member] Grant Date 25-Nov-24 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-two [Member] Grant Date 21-Mar-24, 22-May-24 [Member] This member stands for a classification of grant date share based payment. Grant date twenty [Member] Grant Date 8-Mar-24 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-six [Member] Grant Date 26-Aug-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-nine [Member] Grant Date 25-Nov-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-one [Member] Grant Date 19-Sep-24 [Member] This member stands for a classification of grant date share based payment. Grant date five [Member] Grant Date 13-Jan-20 [Member] This member stands for a classification of grant date share based payment. Grant date eighteen [Member] Grant Date 31-Oct-23 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-seven [Member] Grant Date 25-Nov-24 [Member] This member stands for a classification of grant date share based payment. Grant date eleven [Member] Grant Date 5-Apr-22 [Member] The date on which share-based payment arrangements are vested, in CCYY-MM-DD format. Date of vesting, share-based payment arrangement Vesting date The number of equity-based payment instruments, that vested during the reporting period. Number of share options vested in share based payment arrangement Vested during the year (in shares) The date on which share-based payment arrangements are expired, in CCYY-MM-DD format. Date of expiry, share based payment arrangement Expiry date Number of options issued under equity incentive plan [Abstract] Number of options issued under EIP [Abstract] This member stands for a classification of grant date share based payment. Grant date seven [Member] Grant Date 27-Jan-21 [Member] This member stands for a classification of grant date share based payment. Grant date four [Member] Grant Date 4-Nov-19 [Member] This member stands for a classification of grant date share based payment. Grant date thirteen [Member] Grant Date 2-May-23 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-three [Member] Grant Date 26-Apr-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-four [Member] Grant Date 17-Oct-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-five [Member] Grant Date 17-Oct-24 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-eight [Member] Grant Date 26-Aug-24 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-nine [Member] Grant Date 26-Aug-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-six [Member] Grant Date 25-Nov-24 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-two [Member] Grant Date 21-Oct-24 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-one [Member] Grant Date 8-Mar-24 [Member] This member stands for a classification of grant date share based payment. Grant date sixteen [Member] Grant Date 18-Oct-23 [Member] This member stands for a classification of grant date share based payment. Grant date fifteen [Member] Grant Date 6-Jul-23 [Member] This member stands for a classification of grant date share based payment. Grant date seventeen [Member] Grant Date 31-Oct-23 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-four [Member] Grant Date 26-Aug-24 [Member] This member stands for a classification of grant date share based payment. Grant date twelve [Member] Grant Date 24-Oct-22 [Member] This member stands for a classification of grant date share based payment. Grant date nineteen [Member] Grant Date 30-Nov-23 [Member] This member stands for a classification of grant date share based payment. Grant date ten [Member] Grant Date 5-Apr-22 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-five [Member] Grant Date 26-Aug-24 [Member] This member stands for a classification of grant date share based payment. Grant date six [Member] Grant Date 1-Jul-20 [Member] This member stands for a classification of grant date share based payment. Grant date eight [Member] Grant Date 27-Jul-21 [Member] This member stands for a classification of grant date share based payment. Grant date twenty-seven [Member] Grant Date 26-Aug-24 [Member] This member stands for a classification of grant date share based payment. Grant Date Forty [Member] Grant Date 25-Nov-24 [Member] This member stands for a classification of grant date share based payment. Grant date nine [Member] Grant Date 27-Jul-21 [Member] This member stands for a classification of grant date share based payment. Grant date thirty-three [Member] Grant Date 21-Oct-24 [Member] This member stands for a classification of grant date share based payment. Grant date fourteen [Member] Grant Date 6-Jul-23 [Member] This member stands for a classification of grant date share based payment. Grant date thirty [Member] Grant Date 19-Sep-24 [Member] This member stands for property. Properties [Member] The amount of reclassifications of right-of-use assets. Reclassifications, right-of-use asset Reclassifications The net book amount for right-of-use asset. Right-of-use asset, net book amount Net book amount The name of the entity which is controlled by another entity. Atonco sas [Member] Atonco SAS [Member] The number of Shares converted from group for trade receivables. Shares Converted for Trade Receivables Number of shares converted for trade receivables (in shares) Price of a single share of a number of stocks of a company. Share price per share Share purchase price (in euros per share) The number of ordinary shares subscribed. Number of ordinary shares subscribed Number of ordinary shares subscribed (in shares) The number of share options fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. Number of share options vested and exercisable in share-based payment arrangement Vested and exercisable (in shares) The number of share options expired and forfeited in a share-based payment arrangement. Number of share options expired and forfeited in share-based payment arrangement Lapsed/forfeited during the year (in shares) Number of options [Abstract] Number of Options [Abstract] The weighted average exercise price of share options vested and exercisable in a share-based payment arrangement. Weighted average exercise price of share options vested and exercisable in share-based payment arrangement Vested and exercisable (in dollars per share) The weighted average exercise price of share options expired and forfeited in a share-based payment arrangement. [Refer: Weighted average [member]] Weighted average exercise price of share options expired and forfeited in share-based payment arrangement Lapsed/forfeited during the year (in dollars per share) Weighted average exercise price [Abstract] Weighted Average Exercise Price [Abstract] The amount of exchange differences in contract liabilities. Exchange differences in contract liabilities Exchange differences The amount of an entity's obligation to transfer goods or services to a customer for which the entity has received consideration. Consideration received in contract liabilities Consideration received The amount of unwind of discount in contract liabilities. Unwind of discount in contract liabilities Unwind of discount The amount of first installment of non reimbursable government grant received. First installment of non reimbursable government grant received This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of increases in foreign exchange rates. Currency risk increase through foreign exchange rates [Member] 10% Increase [Member] This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of decreases in foreign exchange rates. Currency risk decrease through foreign exchange rates [Member] 10% Decrease [Member] The percentage of cash held in foreign currency. Percentage of cash held in foreign currency Percentage of cash in foreign currency The amount of foreign currency receivables and financial assets exceeding the amount of payables. Surplus of foreign currency receivables and financial assets over payables Surplus of foreign currency receivables and financial assets over payables Foreign currency risk [Abstract] Impact on post-tax profit/(loss) [Abstract] The entire disclosure for contract liabilities. Disclosure of contract liabilities explanatory [Text Block] Contract liabilities The percentage of net revenue payable in cash as performance-based payments to the seller during the revenue sharing period from the closing date. Percentage of net revenue payable in cash as performance-based payments Percentage of net revenue payable in cash as performance-based payments The revenue sharing period measured as period of time, for performance-based payments payable in cash to seller, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Revenue sharing period Revenue sharing period Amount of increase (decrease) in customer relationships for fair value adjustment in a business combination. Fair value adjustment, customer relationships Customer relationships Amount of increase (decrease) in brand names for fair value adjustment in a business combination. Fair value adjustment, brand name Brand name The earn-out termination period measured as period of time for All earn-outs which are not expired, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Termination period of earn-outs Termination period of earn-outs Amount of increase (decrease) in property, plant and equipment for fair value adjustment in a business combination. Fair value adjustment, property, plant and equipment Property, plant and equipment The amount recognized as of the acquisition date for right-of-use assets acquired in a business combination. Right-of-use assets recognized as of acquisition date Right-of-use assets Net amount of increase (decrease) in assets and liabilities for fair value adjustment in a business combination. Fair value adjustments recognized as of acquisition date Total fair value adjustments The amount recognized as of the acquisition date for lease obligation assumed in a business combination. Lease liabilities adjustments recognized as of acquisition date Lease liabilities Amount of increase (decrease) in deferred tax liabilities for fair value adjustment in a business combination. Fair value adjustment, deferred tax liability Deferred tax liabilities Amount of increase (decrease) in intellectual property for fair value adjustment in a business combination. Fair value adjustment, intellectual property Intellectual property The increase (decrease) in revenue of the combined entity as though the acquisition date of the business combinations that occurred during the year had been as of the beginning of the annual reporting period. Increase (decrease) of revenue of combined entity Preliminary assessment of higher group revenue Amount of increase (decrease) in inventories for fair value adjustment in a business combination. Fair value adjustment, Property, inventories Inventories Fair value adjustments [Abstract] Fair value adjustments [Abstract] The increase (decrease) in profit (loss) before tax of the combined entity as though the acquisition date for the business combination that occurred during the year had been as of the beginning of the annual reporting period. Increase (decrease) of profit (loss) before tax of combined entity Preliminary assessment of lower group profit before tax The fair value of performance rights issued by acquiree in the consideration at the date of acquisition. Performance rights issued as of acquisition date Performance rights issued The amount recognized as of the acquisition date for trade and other receivables acquired in a business combination. Trade and other receivables recognized as of acquisition date Trade and other receivables The fair value, at acquisition date, of the final consideration transferred in a business combination. Acquisition date fair value of final purchase price consideration Final purchase price Acquisition [Abstract] Acquisition [Abstract] The disclosure of the reconciliation of profit (loss) after income tax to net cash from (used in) operating activities. Disclosure of reconciliation of profit (loss) after income tax to net cash from (used in) operating activities [Table Text Block] Reconciliation of Profit/(Loss) After Income Tax to Net Cash From/(Used in) Operating Activities Number of performance right granted in share-based payment arrangement. Number of performance right granted in share-based payment arrangement Performance rights issued (in shares) Share-based payments reserve [Abstract] Share-based payments reserve [Abstract] The tabular disclosure of other (losses) gains net. Disclosure of other (losses) gains, net [Table Text Block] Other (Gains)/Losses (net) A component of equity representing the financial assets at fair value through other comprehensive income(FVOCI) reserve. Reserve of financial assets at fair value through other comprehensive income Beginning balance Ending balance Financial assets at FVOCI reserve [Abstract] Financial assets at FVOCI reserve [Abstract] The amount of change in provisions of property, plant and equipment. Change in provisions, property, plant and equipment Change in provisions Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale Property, plant and equipment, cost Cost Amount of accumulated depreciation for physical assets used in the normal conduct of business to produce goods and services. Accumulated depreciation property plant And equipment Accumulated depreciation This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations and plant and equipment. Land and buildings and plant and equipment [Member] Land and Buildings and Plant and Equipment [Member] This member stands for relation to the build-out of Brussels South in the course of its construction. Brussels South [Member] Brussels South [Member] The disclosure of detailed information about convertible bonds reported in statement of financial position. Disclosure of detailed information about convertible bonds reported in statement of financial position [Table Text Block] Convertible Bonds Presented in Statement of Financial Position The disclosure of maturity analysis for borrowings from lenders. Disclosure of detailed information about maturity analysis for borrowings from lenders [Table Text Block] Maturity Analysis for Borrowings From Lenders The disclosure of detailed information about carrying amount and fair value of convertible bonds. Disclosure of detailed information about carrying amount and fair value of convertible bonds [Table Text Block] Convertible Bonds Carrying Amount and Fair Value The amount of current secured working capital facility current received and the current portion of non-current secured working capital facility current received. Secured working capital facility current Secured working capital facility current The amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets. Secured borrowings non current Total secured borrowings non current long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower. Secured borrowings current Total secured borrowings current The amount of uncollateralized debt obligation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Unsecured borrowings non current Total unsecured borrowings non current long-term, uncollateralized debt obligations due within one year or the normal operating cycle, if longer. Unsecured borrowings current Total unsecured borrowings current The non-current portion of non-current secured working capital facility received. Secured working capital facility non-current Secured working capital facility non-current The conversion nominal value per share. Conversion price Conversion price (in dollars per share) The nominal or face amount of a financial instrument, used to calculate payments made on that instrument. Face value of convertible bonds issued Face value of convertible bonds issued Description of the frequency of periodic payments (monthly, quarterly, annual). Borrowing interest frequency of periodic payment Debt interest frequency of payment The cash outflow for interest paid on convertible debt, classified as operating activities. Interest paid on convertible bonds classified as operating activities Interest paid The increase (decrease) in equity resulting from the conversion of performance rights. Other equity securities value of conversion rights Other equity securities - value of conversion rights The convertible bonds maturity of in YYYY format. Convertible bonds maturity year Convertible bonds maturity year Convertible bonds [Abstract] A type of financial measurement used in finance, business, and economics to evaluate the level of debt relative to another financial metric. leverage ratio Leverage ratio Capital risk management [Abstract] Capital risk management [Abstract] The member stands for Bank Loans. Bank loans [Member] Bank loans [Member] The member stands for services of radiopharmaceutical production facility. Radiopharmaceutical production facility [Member] Radiopharmaceutical Production Facility [Member] This member stands for convertible bonds. Convertible bonds [Member] Convertible Bonds [Member] This member stands for the name of financial institution which company made loan agreement. BNP Paribas and IMBC Group [Member] BNP Paribas and IMBC Group [Member] The number of loan agreements. Number of loan agreements Number of loan agreements The repayment period of loan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Loan repayment period Loan repayment period The maturity term of borrowings, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Borrowings, maturity term Borrowings, maturity term The percentage of capital and reserves. Capital and reserves, percentage Capital and reserves percentage Bank loans [Abstract] Bank loans [Abstract] The maximum period of measurement from the date of acquisition to the date the group obtains complete information about facts and circumstances that existed as of the acquisition date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Maximum measurement period Maximum measurement period The description of the entity's accounting policy for principles of consolidation. Description of accounting policy for principles of consolidation [Policy Text Block] Principles of consolidation The description of the entity's accounting policy for the basis of preparation. Description of accounting policy for basis of preparation [Policy Text Block] Basis of preparation The description of the entity's material accounting policy information for non-current financial assets. Description of accounting policy for non-current financial assets [Policy Text Block] Non-current financial assets The description of the entity's accounting policy for the basis for how the entity classifies assets and liabilities as current and non-current. Description of accounting policy for classification of assets and liabilities [Policy Text Block] Current and non-current classification The description of the entity's material accounting policy information for lease liabilities. Description of accounting policy for lease liabilities [Policy Text Block] Lease liabilities The description of the entity's material accounting policy information for right-of-use assets. Description of accounting policy for right-of-use assets [Policy Text Block] Right-of-use assets The description of the entity's accounting policy for going concern. Description of accounting policy for going concern [Policy Text Block] Going concern The description of the entity's material accounting policy information for significant changes in the current or prior reporting period. Description of accounting policy for significant changes in the current or prior reporting period [Policy Text Block] Significant changes in the current or prior reporting period The unallocated expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment. Unallocated employment costs Unallocated employment costs The amount of expenditure directly attributable to unallocated general and administration cost activities, recognized in profit or loss. Unallocated general and administration cost General and administration costs Unallocated income, eliminations and expenses [Abstract] Unallocated income, expenses and eliminations [Abstract] The unallocated gains (losses) that the entity does not separately disclose in the same statement or note. Unallocated other gains (losses) Other gains/(losses) (net) The unallocated amount of depreciation and amortization expense. Unallocated depreciation and amortisation expense Depreciation and amortization The amount of expenditure directly attributable to unallocated general and administration costs activities, recognized in profit or loss. Unallocated general and administration costs General and administration costs Unallocated income, expenses and eliminations [Abstract] Unallocated income, expenses and eliminations [Abstract] Reconciliation of total segment adjusted EBITDA and group adjusted EBITA to profit/(loss) before income tax [Abstract] Reconciliation of Total Segment Adjusted EBITDA and Group Adjusted EBITA to Profit/(Loss) Before Income Tax [Abstract] Adjustments for increase (decrease) in provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments for increase decrease in provisions (Decrease) in provisions Adjustments for unwind of discount to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments for unwind of discount Unwind of discount Adjustments for contingent consideration to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments for contingent consideration Fair value remeasurement of contingent consideration The amount of impairment(reversal) recognized in profit or loss for intangible assets. Impairment(reversal) of intangible assets Adjustments for decrease (increase) in trade creditors to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments for decrease (increase) in trade creditors Increase in trade creditors Adjustments for decrease (increase) in other non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. Adjustments for decrease (increase) in other non-current assets (Increase) in other non-current assets Change in assets and liabilities [Abstract] Change in assets and liabilities [Abstract] The name of financial institution which company made an first loan agreement. IMBC Group [Member] The non-current portion of non-current borrowings(overpayments). Non-current borrowings(overpayments) Due greater than 1 year This member stands for the name of financial institution which company made loan agreement. HSBC Australia Ltd [Member] This member stands for the name of financial institution which company made loan agreement. The Hongkong and Shanghai Banking Corporation Limited as the Trustee for Convertible Bond Holders [Member] This member stands for the name of financial institution which company made loan agreement. BNP Paribas [Member] BNP Paribas [Member] This member stands for the name of financial institution which company made loan agreement. J.P. Morgan Securities Plc as the Manager for convertible bond holders [Member] The maximum borrowings capacity amount. Maximum borrowings capacity Facility limit The amount of outstanding funds that the entity is obligated to repay. Borrowings(overpayments) Total loan balance Borrowings lender [Abstract] Borrowings lender [Abstract] Auditors' remuneration disclosure [Abstract] Remuneration of Auditor [Abstract] This member stands for other auditors and their related network firms. Other auditors and their related network firms [Member] Other Auditors and their Related Network Firms [Member] This member stands for Auditors of the Group - Pricewaterhouse Coopers Australia and related network firms providing auditing services. Pricewaterhouse Coopers australia and related network firms [Member] Auditors of the Group - PricewaterhouseCoopers Australia and Related Network Firms [Member] The amount of lease liabilities increased through acquisition of business. Lease liabilities increased through acquisition of business Acquisition of businesses The increase (decrease) in right-of-use assets resulting from net exchange differences. Increase Decrease Through Exchange Differences Right Of Use Assets Exchange differences Lease payments [Abstract] Lease Payments [Abstract] An entity associated with one or more key management personnel of the reporting entity. ABX-CRO [Member] ABX-CRO [Member] The term of the note issued for consideration payable for the acquisition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Business acquisition, consideration term Acquisition term The amount of compensation to key management personnel in the form of purchases of goods and services. Key management personnel, purchases of goods and services related party transactions Purchases of various goods and services from entities controlled by key management personnel The amount paid as part of this consultancy agreement compensation to key management personnel. Key management personnel compensation, consulting agreement fees, paid Consultancy agreement fee paid The amount of upfront cash consideration to share of profits generated from QDOSE sales and a referral fee on deals. Upfront cash consideration Upfront cash consideration The amount of compensation to key management personnel in the form of consulting fees. [Refer: Key management personnel of entity or parent [member]]. Key management personnel compensation consulting fees Consultancy agreement fees The tabular disclosure commitments estimated based on the contractual obligations. Disclosure of commitments, contractual obligations explanatory [Text Block] Estimated Based on Contractual Obligations This member stands for a component of equity resulting from financial assets at fair value through other comprehensive income(FVOCI) reserve. Reserve of financial assets at fair value through other comprehensive income [Member] Financial Assets at FVOCI Reserve [Member] Other reserves [Abstract] Other reserves [Abstract] The cash outflow for the purchase of decommissioning liability, classified as investing activities. Purchase of decommissioning liability, classified as investing activities Payments for decommissioning liability The cash outflow for the purchase of contingent consideration, classified as investing activities. Purchase of contingent consideration, classified as investing activities Payments for contingent consideration The cash inflow in relation to research and development tax incentive. Receipts in relation to research and development tax incentive Receipts in relation to R&D tax incentive The cash outflow for payments to contingent consideration, classified as operating activities. Payments for contingent consideration, classified as operating activities Payments for contingent consideration Contingent consideration payments classified as operating The disclosure of detailed information about trade and other receivables. Disclosure of detailed information about trade and other receivables explanatory [Table Text Block] Trade and Other Receivables Comprehensive income from continuing operations [Abstract] Continuing operations The disclosure of detailed information about inventories. Inventories current [Table Text Block] Inventories The amount of revenue arising from provision of services. Revenue from provision of services Provision of services The amount of income arising from research and development services. Research and development services Research and development services The amount of revenue arising from licenses of intellectual property. Licenses of intellectual property Licenses of intellectual property A classification of current inventory representing the amount of provision for obsolescence. Provision for obsolescence Provision for obsolescence The increase (decrease) in equity resulting from the transfer on exercise of options. Increase (decrease) through transfer on exercise of options, equity Transfer on exercise of options The increase (decrease) in equity resulting from share-based payment transactions associated with acquisitions. Increase (decrease) through share-based payment transactions associated with acquisitions, equity Share-based payments associated with acquisitions The increase (decrease) in equity resulting from the transaction costs arising on Convertible Bonds Issue. Increase Decrease Through Transaction Costs Arising On Convertible Bonds Issue Transaction costs arising on convertible bonds issue The entire disclosure for corporate information. Disclosure of corporate information explanatory [Text Block] Corporate Information Corporate information [Abstract] The disclosure of detailed information about other current assets. Disclosure of detailed information about other current assets [Table Text Block] Other Current Assets The increase (decrease) in the number of shares issued. Increase (decrease) in number of shares issued Shares issued (in shares) Volume weighted average period in in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Volume weighted average period Volume weighted average period This member stands for a business combination. ARTMS Inc [Member] ARTMS [Member] ARTMS Inc [Member] The name of the entity which is controlled by another entity. QSAM Biosciences, Inc [Member] QSAM Biosciences [Member] QSAM Biosciences, Inc [Member] The name of the entity which is controlled by another entity. Lightpoint Medical [Member] Lightpoint Medical [Member] The increase (decrease) in equity resulting from the transaction costs arising on new share issues. Increase (decrease) in transaction costs arising on new share issues Transaction costs arising on new share issues Number of shares increase (decrease) in transaction costs arising on new share issues. Increase (decrease) in transaction costs arising on new share issued Transaction costs arising on new share issues (in shares) The value of shares issued under contributions of equity. Increase (decrease) through contributions of equity Contributions of equity The 10-day volume weighted average price of other equity instruments. Volume weighted average price of equity instruments Volume weighted average price (in dollars per share) Value of shares issued as a result of the exercise of stock options and warrants. Shares issued through exercise of share options and warrants Shares issued through the exercise of share options and warrants The increase (decrease) in the number of shares issued under contributions of equity shares. Increase (decrease) through contributions of equity shares Contributions of equity (in shares) Shares issued as a result of the exercise of stock options and warrants. Increase (decrease) shares issued through exercise of share options and warrants Shares issued through the exercise of share options and warrants (in shares) The cash outflow for institutional placement cost. Payments for institutional placement cost Institutional placement cost Cash flow information [Abstract] Key management personnel compensation [Abstract] The disclosure of detailed information about the numerical reconciliation of prima facie tax payable to income tax benefit. Disclosure of detailed information about numerical reconciliation of prima facie tax payable to income tax benefit expense explanatory [Table Text Block] Numerical Reconciliation of Prima Facie Tax Payable to Income Tax Expense/(Benefit) The disclosure of detailed information about income tax benefit (expense). Disclosure of detailed information about income tax benefit expense explanatory [Table Text Block] Income Tax Expense/(Benefit) The amount of expenses relating to rent and insurances. Rent and insurance costs Rent and insurance The amount of expense recognised on information technology infrastructure, hosting and support services. Information technology infrastructure hosting and support expenses IT infrastructure, hosting and support The amount of expense recognised on travel, conferences and entertainment activities. Travel conferences and entertainment costs Travel, conferences and entertainment The amount of expenses relating to marketing and sponsorship. Marketing and sponsorship costs Marketing and sponsorship The amount of expense recognised on listing costs. Listing costs U.S. listing costs Interest expense relating to leases [Abstract] Interest Expense Relating to Leases [Abstract] This member stands for decommissioning liability aggregated categories of financial liabilities. Decommissioning liability [Member] Decommissioning Liability [Member] The risk adjusted discount rate used in expected sales volumes and the net sales price per unit. Risk adjusted discount rate Risk adjusted discount rate The amount of decommissioning costs expected to be incurred. Decommissioning costs expected to be incurred Total decommissioning costs expected to be incurred Amount of increase (decrease) in other provision adjusted to intangible assets. Increase (decrease) in other provision adjusted to intangible assets Amounts adjusted to intangible assets Amount of increase (decrease) in other provision adjusted to property plant and equipment. Increase (decrease) in other provision adjusted to property plant and equipment Amounts adjusted to property, plant and equipment The amount of other provisions charged to profit (loss). Other provisions charged to profit (loss) Charged to profit or loss Percentage of risk-free rate used to discount the decommissioning costs. Risk-free rate Risk-free rate The increase (decrease) in other provisions resulting from remeasurement of provision. Increase decrease through remeasurement of other provisions Remeasurement of provisions The amount of non-current Long service leave employee benefit obligations. Long service leave Long service leave The amount of current annual leave employee benefit obligations. Annual leave Annual leave The amount of current and non-current provisions for employee benefit obligations. Employee benefit obligations Total employee benefit obligations The amount of current bonus employee benefit obligations. Bonus Bonuses The amount of assets that do not meet the definition of current assets by location of assets. Non-current assets by location of asset Non-current assets by location of asset Geographical information [Abstract] Geographical Information [Abstract] The normal settlement period for trade and other payables, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Settlement period of trade and other payables Settlement period of trade and other payables Name of the entity controlled by another entity. RLS (USA) Inc [Member] RLS (USA) Inc [Member] The percentage of concentration of major credit risk. Percentage of major credit risk Percentage of major credit risk The entire disclosure of depreciation and amortization expense. Disclosure of depreciation and amortization [Text Block] Depreciation and amortization Other (gains)/losses (net) [Abstract] Commitments [Abstract] This member stands for a medical segment which deals of medicine concerned with the treatment of disease and the action of remedial agents. The Therapeutics segment focuses on the development of company core therapeutic pipeline for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services. This segment includes the development activities of the Group's pivotal therapeutic pipeline. Therapeutics [Member] Therapeutics [Member] This member stands for a segment which deals with is a medical model that separates people into different groups-with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. This segment focus on Commercial sales of Illuccix and other diagnostic products subsequent to obtaining regulatory approvals. This segment also includes the development activities of the Group's diagnostic pipeline. Precision medicine [Member] Precision Medicine [Member] This member stands for a segment which deals with global network of facilities designed to deliver patient doses worldwide and comprises costs to operate company facilities and assets associated with the Group's vertically integrated manufacturing and supply chain. Manufacturing solutions [Member] Manufacturing Solutions [Member] Reportable segments [Abstract] Reportable Segments [Abstract] The number of segments that an entity operates in business. Number of segments Number of reporting segments The amount of expense relating to manufacturing and distribution of goods and services of the entity. Manufacturing and distribution costs Manufacturing and distribution costs The gains (losses) that the entity does not separately disclose in the operating activities of the entity. Other gains (losses) in operating activity Other losses (net) The amount of expense relating to selling and marketing activities of the entity. Selling and marketing expenses Selling and marketing expenses The amount of adjusted earnings before interest, tax, depreciation and amortization of the entity. Adjusted earnings before interest, tax, depreciation and amortization Adjusted earnings before interest, tax, depreciation and amortization Total segment adjusted EBITDA Material accounting policy information [Abstract] This member stands for leased plant and equipment. Leased plant and equipment [Member] Leased Plant and Equipment [Member] Commitments and contingencies [Table] Line items represent concepts of commitments. Commitments and contingencies [Line Items] The amount of research and developments commitments contractual obligations for which the entity has committed. Research and developments commitments contractual obligations R&D commitments This member stands for a class of intellectual properties. Intellectuals properties [Member] Intellectual Property [Member] This member stands for a class of intangible assets representing patents, trademarks, licenses and customer contracts. Patents, trademarks, licenses and customer contracts [Member] Patents, Trademarks, Licenses and Customer Contracts [Member] Contingent consideration [Abstract] The entire disclosure of contingent consideration during the year. Disclosure of contingent consideration explanatory [Text Block] Contingent consideration Detailed information about contingent consideration [Table] Detailed information about contingent consideration [Table] This member stands for transactions or other events in which an acquirer obtain control of business. ANMI [Member] ANMI [Member] This member stands for transactions or other events in which an acquirer obtain control of business. Optimal tracers [Member] Optimal Tracers [Member] This member stands for transactions or other events in which an acquirer obtain control of business. TheraPharm [Member] TheraPharm [Member] Detailed information about contingent consideration [Line Items] Tabular disclosure of information about contingent consideration valuation. Schedule of contingent consideration valuation [Table Text Block] Contingent Consideration Valuation Tabular disclosure of information about contingent consideration. Schedule of contingent consideration explanatory [Table Text Block] Contingent Consideration This member stands for a product or business unit. ARTMS [Member] ARTMS [Member] The amount of current contingent consideration. Current contingent consideration Contingent consideration Current The amount of current employee benefit obligations. Current employee benefit obligations Employee benefit obligations Current The non-current portion of non-current employee benefit obligations. Non-current employee benefit obligations Employee benefit obligations Non-current The non-current portion of non-current contingent consideration. Non-current contingent consideration Contingent consideration Non-current A component of equity representing the capital reserves(deficit). Capital reserve(deficit) Share capital reserve Beginning balance Ending balance Finance costs [Abstract] Research and development costs [Abstract] The disclosure of detailed information about research and development costs. Disclosure of detailed information about research and development costs explanatory [Text Block] Research and Development Costs The disclosure of detailed information about finance costs. Disclosure of detailed information about finance costs [Table Text Block] Finance Costs This member stands for an reporting segment of the entity which developing radiopharmaceutical products for commercialization. This segment includes revenue received from license agreements prior to commercialization and research and development services. Product development [Member] Product Development [Member] This member stands for clinical products used for therapeutic and diagnostic applications. TLX250 and TLX101 [Member] TLX250, TLX101 (Phase 2) [Member] This member stands for clinical products used for therapeutic and diagnostic applications. Pixclara, Zircaix, Gozelix [Member] Pixclara, Zircaix, Gozelix (Pre-Commercial) [Member] This member stands for clinical products used for therapeutic and diagnostic applications. Pre-clinical research and innovation [Member] Pre-clinical Research and Innovation [Member] This member stands for clinical product used for therapeutic and diagnostic applications. TLX591 [Member] TLX591 (Phase 3) [Member] TLX591 [Member] This member stands for clinical products used for therapeutic and diagnostic applications. TLX66 and TLX300 [Member] TLX66, TLX300 (Phase 1) [Member] This member stands for pre-clinical expenses and research expenditure on novel targets and technologies. Other research and development projects [Member] Other Research and Development Projects [Member] This member stands for clinical products used for therapeutic and diagnostic applications. Illuccix, TLX591-CDx [Member] Illuccix, TLX591-CDx (Commercial) [Member] Sales of goods [Abstract] Sales of goods [Abstract] The credit term for sale of goods, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Sales of goods, credit term Sales of goods, credit term The risk adjusted post tax discount rate used in contingent consideration valuation. Risk adjusted post tax discount rate Risk adjusted post tax discount rate Amount of milestone payment on receipt of second marketing approval. Milestone payment on receipt of second marketing approval Milestone payment on receipt of second marketing approval This member stands for expected sales volume used as a measurement input. Expected sales volume [Member] Expected Sales Volume [Member] The amount of increase (decrease) in net sales price per unit would increase decrease the contingent consideration. Amount of increase (decrease) in net sales price per unit would increase (decrease) contingent consideration Amount of increase / (decrease) in net sales price per unit would increase / (decrease) contingent consideration This member stands for a post tax discount rate used as a measurement input used in valuation techniques. Risk adjusted post tax discount rate [Member] Risk Adjusted Post Tax Discount Rate [Member] Risk Adjusted Post Tax Discount Rate [Member] The period for future variable payments, which are calculated based on a percentage of net sales, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Future variable payments The amount of increase (decrease) in sales volumes would increase decrease the contingent consideration. Amount of increase (decrease) in sales volumes would increase (decrease) contingent consideration Amount of increase / (decrease) in sales volumes would increase / (decrease) contingent consideration The percentage of net sales for first three years after business acquisition. Percentage of net sales Threshold sales percentage for first approval The amount of increase (decrease) in probability of success factor would increase decrease the contingent consideration. Amount of increase (decrease) in probability of success factor would increase (decrease) contingent consideration Amount of increase / (decrease) in probability of success factor would increase / (decrease) contingent consideration The amount of increase (decrease) in post-tax discount rate would (decrease) increase the contingent consideration. Amount of increase (decrease) in post-tax discount rate would (decrease) increase contingent consideration Amount of increase / (decrease) in post-tax discount rate would (decrease) / increase contingent consideration This member stands for net sales price per unit used as a measurement input. Net sales price per unit [Member] Net Sales Price Per Unit [Member] Net Sales Price Per Unit [Member] Amount of milestone payment on completion of Phase III pivotal registration trial. Milestone payment on completion of phase III pivotal registration trial Milestone payment on completion of phase III pivotal registration trial This member stands for approval for marketing authorization probability success factor used as a measurement input. Approval for marketing authorization probability success factor [Member] Approval for Marketing Authorization Probability Success Factor [Member] The period for option to buy-out the remaining future variable payments which are calculated based on a percentage of net sales, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Option to buy-out remaining future variable payments Tax effect of amounts which are not deductible (taxable) in calculating taxable income [Abstract] The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share-based payments expense. Tax effect of Share-based payments expense Share-based payments expense The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to R&D tax incentive credit. Tax effect of net R&D tax incentive credit Net R&D tax incentive credit The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to employee share trust payments. Tax effect of employee share trust payments Employee Share Trust payments The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to remeasurement of provisions. Tax effect of remeasurement of provisions Remeasurement of provisions The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to exchange translation loss. Tax effect of exchange translation loss Foreign exchange translation loss This member stands for a business combination. ISO Therapeutics Group, LLC [Member] Iso Therapeutics Group, LLC [Member] Iso Therapeutics [Member] The amount of unwind of discount on contingent consideration liabilities. Unwind of discount on contingent consideration liabilities The amount of unwind of discount on provisions. Unwind of discount on Provisions Unwind of discount on provisions The amount of unwind of discount on convertible bonds during the year. Unwind of discount on convertible bonds Unwind of discount on convertible bonds The amount of unwind of discount on contract liabilities. Unwind of discount on contract liabilities Unwind of discount on contract liabilities Finance cost [Abstract] The amount of unwind of discount in finance cost. Unwind of discount The amount of potential milestone payments to a licensor in order to acquire regulatory approval. Potential milestone payment of license fee Potential milestone payment of license fee The amount of potential milestone payments of relation to clinical data used in the new drug application (NDA). Potential milestone payment of clinical data used in NDA Potential milestone payment to clinical data used in NDA Interests in other entities [Abstract] Interests in other entities [Abstract] The name of the entity which is controlled by another entity. Telix Pharma Japan KK [Member] Telix Pharma Japan KK [Member] The name of the entity which is controlled by another entity. Telix Optimal Tracers, LLC [Member] Telix Optimal Tracers, LLC [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (France) SAS [Member] Telix Pharmaceuticals (France) SAS [Member] The name of the entity which is controlled by another entity. Telix ARTMS Inc. [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals Holdings Pty Limited [Member] Telix Pharmaceuticals Holdings Pty Ltd [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Belgium) SRL [Member] Telix Pharmaceuticals (Belgium) SRL [Member] The name of the entity which is controlled by another entity. Dedicaid GmbH [Member] Dedicaid GmbH [Member] The name of the entity which is controlled by another entity. Lightpoint Surgical Ltd [Member] Lightpoint Surgical Ltd [Member] The name of the entity which is controlled by another entity. ARTMS US, Inc. [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (ANZ) Pty Ltd [Member] Telix Pharmaceuticals (ANZ) Pty Ltd [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals Australia Holdings Pty Limited [Member] Telix Pharmaceuticals Australia Holdings Pty Ltd [Member] The name of the entity which is controlled by another entity. QSAM Therapeutics Inc. [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (US) Inc. [Member] Telix Pharmaceuticals (US) Inc. [Member] The name of the entity which is controlled by another entity. Telix Innovations SA [Member] Telix Innovations SA [Member] The name of the entity which is controlled by another entity. Lightpoint Surgical Spain S.L. [Member] Lightpoint Surgical Spain S.L. [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Canada) Inc. [Member] Telix Pharmaceuticals (Canada) Inc. [Member] The name of the entity which is controlled by another entity. Rhine Pharma GmbH (formerly Telix Pharmaceuticals (Germany) GmbH) [Member] Rhine Pharma GmbH [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals International Holdings Pty Limited [Member] Telix Pharmaceuticals International Holdings Pty Ltd [Member] The name of the entity which is controlled by another entity. Telix IsoTherapeutics Group, Inc. [Member] Telix IsoTherapeutics Group, Inc. [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Singapore) Pte Ltd [Member] Telix Pharmaceuticals (Singapore) Pte Ltd [Member] The name of the entity which is controlled by another entity. Therapeia GmbH & Co. KG [Member] Therapeia GmbH & Co. KG [Member] The name of the entity which is controlled by another entity. Telix QSAM, Inc. [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals Ltd [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (UK) Ltd (formerly Telix Life Sciences (UK) Ltd) [Member] Telix Pharmaceuticals (UK) Ltd [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Corporate) Pty Limited [Member] Telix Pharmaceuticals (Corporate) Pty Ltd [Member] The name of the entity which is controlled by another entity. Telix Innovations Rph Participacoes Ltd [Member] Telix Innovations Rph Participacoes Ltd [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (NZ) Limited [Member] Telix Pharmaceuticals (NZ) Ltd [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Germany) GmbH [Member] Telix Pharmaceuticals (Germany) GmbH [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Innovations) [Member] Telix Pharmaceuticals (Innovations) [Member] The name of the entity which is controlled by another entity. Therapeia Verwaltungs-GmbH [Member] The name of the entity which is controlled by another entity. Telix Pharmaceuticals (Switzerland) GmbH [Member] Telix Pharmaceuticals (Switzerland) GmbH [Member] This member stands for government grant liability aggregated categories of financial liabilities. Government grant liability [Member] Government Grant Liability [Member] Government Grant Liability [Member] This member stands for trade and other payables. Trade and other payables [Member] Trade and Other Payables [Member] This member stands for long-term and short-term borrowing. Borrowing [Member] Borrowings [Member] Business acquisition amount of contingent consideration recognized. Contingent consideration Contingent consideration Contingent consideration liability Beginning balance Ending balance Operating segment assets and liabilities [Abstract] Operating Segment Assets and Liabilities [Abstract] Concentration of Credit Risk [Abstract] Concentration of credit risk [Abstract] The percentage of concentration of credit risk. Percentage of credit risk Percentage of credit risk Ageing of trade receivables [Abstract] The amount of an allowance account used to record impairments to financial assets due to credit losses. Allowance for credit losses of financial assets Expected credit losses Allowance for impairment losses Expected credit losses Represents the number of distributors during the period. Number of distributors Number of distributors